Cargando…

Antiplatelet medications and risk of intracranial hemorrhage in patients with metastatic brain tumors

Although intracranial hemorrhage (ICH) is frequent in the setting of brain metastases, there are limited data on the influence of antiplatelet agents on the development of brain tumor–associated ICH. To evaluate whether the administration of antiplatelet agents increases the risk of ICH, we performe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, Eric J., Patell, Rushad, Uhlmann, Erik J., Ren, Siyang, Southard, Hannah, Elavalakanar, Pavania, Weber, Griffin M., Neuberg, Donna, Zwicker, Jeffrey I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905695/ https://www.ncbi.nlm.nih.gov/pubmed/35086145 http://dx.doi.org/10.1182/bloodadvances.2021006470

Ejemplares similares

Anticoagulation after intracranial hemorrhage in brain tumors: Risk of recurrent hemorrhage and venous thromboembolism
por: Carney, Brian J., et al.
Publicado: (2020)

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
por: Vijenthira, Abi, et al.
Publicado: (2020)

COVID‐19 and venous thromboembolism: A narrative review
por: Angelini, Dana E., et al.
Publicado: (2022)

Venous thromboembolism prophylaxis for hospitalized adult patients: a survey of US health care providers on attitudes and practices
por: Lam, Barbara D., et al.
Publicado: (2023)

Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study
por: Khan, Adeel M., et al.
Publicado: (2022)

The prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis
por: Hsu, Charles, et al.
Publicado: (2022)

Postdischarge thrombosis and hemorrhage in patients with COVID-19
por: Patell, Rushad, et al.
Publicado: (2020)

Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials
por: Shimony, Shai, et al.
Publicado: (2023)

Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
por: Shimony, Shai, et al.
Publicado: (2022)

Development and performance of a hereditary hemorrhagic telangiectasia-specific quality-of-life instrument
por: Kasthuri, Raj S., et al.
Publicado: (2022)

Venous Thromboembolism in Total Hip and Total Knee Arthroplasty
por: Simon, Samantha J., et al.
Publicado: (2023)

Heparin-induced thrombocytopenia in patients with COVID-19: a systematic review and meta-analysis
por: Uaprasert, Noppacharn, et al.
Publicado: (2021)

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
por: Penter, Livius, et al.
Publicado: (2021)

Utilization of a Resuscitative Care Unit for Initial Triage, Management, and Disposition of Minor Intracranial Hemorrhage
por: Joseph, Jacob R., et al.
Publicado: (2020)

Impact of Paxlovid on international normalized ratio among patients on chronic warfarin therapy
por: Muse, Oluwatoyosi, et al.
Publicado: (2022)

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
por: Derman, Benjamin A., et al.
Publicado: (2023)

Routine platelet transfusion in patients with traumatic intracranial hemorrhage taking antiplatelet medication: Is it warranted?
por: Wolff, Christopher, et al.
Publicado: (2022)

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
por: Frigault, Matthew J., et al.
Publicado: (2022)

Analysis of traumatic intracranial hemorrhage and delayed traumatic intracranial hemorrhage in patients with isolated head injury on anticoagulation and antiplatelet therapy
por: Raymond, Kevin, et al.
Publicado: (2023)

Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention
por: Hamilton, Betty K., et al.
Publicado: (2023)

Early cessation of calcineurin inhibitors is feasible post–haploidentical blood stem cell transplant: the ANZHIT 1 study
por: Moore, John, et al.
Publicado: (2023)

Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial
por: Hoshino, Haruhiko, et al.
Publicado: (2021)

Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT
por: Kinoshita, Hannah, et al.
Publicado: (2022)

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
por: Garcia, Jacqueline S., et al.
Publicado: (2021)

Antiplatelet therapy is associated with a high rate of intracranial hemorrhage in patients with head injuries
por: Alter, Scott M, et al.
Publicado: (2020)

Prestroke Antiplatelet Effect on Symptomatic Intracranial Hemorrhage and Functional Outcome in Intravenous Thrombolysis
por: Choi, Jay Chol, et al.
Publicado: (2016)

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
por: Freeman, Sylvie D., et al.
Publicado: (2023)

ARCTIC: Additional proof against antiplatelet adjusted therapy
por: Elmahdy, Mahmoud Farouk, et al.
Publicado: (2013)

Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells
por: van Bruggen, J. A. C., et al.
Publicado: (2022)

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
por: Döhner, Hartmut, et al.
Publicado: (2022)

Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation
por: Scordo, Michael, et al.
Publicado: (2022)

Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial
por: Li, Yi, et al.
Publicado: (2020)

Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma
por: Voorhees, Timothy J., et al.
Publicado: (2022)

Tracking the progeny of adoptively transferred virus-specific T cells in patients posttransplant using TCR sequencing
por: Huisman, W., et al.
Publicado: (2022)

Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis
por: Ataga, Kenneth I., et al.
Publicado: (2022)

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
por: Agbuduwe, Charles, et al.
Publicado: (2022)

Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
por: Smith, Catherine C., et al.
Publicado: (2022)

Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial
por: Rijneveld, Anita W., et al.
Publicado: (2022)

Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant
por: Chung, David J., et al.
Publicado: (2022)

Economic evaluation of regular transfusions for cerebral infarct recurrence in the Silent Cerebral Infarct Transfusion Trial
por: Hsu, Peter, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m8dq1ap6ocbe3b3aqm52fcm1i5